1-3 of 3
Eleonora Perotta
Close
Sort by
Journal Articles

Outcomes of Venetoclax Retreatment after MRD-Guided Venetoclax +/- Ibrutinib: Results of the Improve Study

Elisa Albi, Lydia Scarfo, Silvia Heltai, Eloise Scarano, Luana Schiattone, Lucia Farina, Riccardo Moia, Marina Deodato, Andrea Ferrario, Marina Motta, Alessandro Noto, Rosaria Sancetta, Marta Coscia, Paolo Rivela, Luca Laurenti, Marzia Varettoni, Eleonora Perotta, Antonella Capasso, Pamela Ranghetti, Francesca Martini, Emanuela Sant'Antonio, Catalina Combi, Maria Colia, Paolo Ghia
Journal: Blood
Blood (2023) 142 (Supplement 1): 6521.
https://doi.org/10.1182/blood-2023-174603
Published: 2023
Journal Articles

Minimal residual disease–driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL

Clinical Trials & Observations
Lydia Scarfò, Silvia Heltai, Elisa Albi, Eloise Scarano, Luana Schiattone, Lucia Farina, Riccardo Moia, Marina Deodato, Andrea Ferrario, Marina Motta, Gianluigi Reda, Rosaria Sancetta, Marta Coscia, Paolo Rivela, Luca Laurenti, Marzia Varettoni, Eleonora Perotta, Antonella Capasso, Pamela Ranghetti, Maria Colia, Paolo Ghia
Journal: Blood
Blood (2022) 140 (22): 2348–2357.
https://doi.org/10.1182/blood.2022016901
Published: 2022
Includes: Supplemental data
Journal Articles

Minimal Residual Disease-Driven Treatment Intensification By Sequential Addition of Ibrutinib to Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of the Monotherapy and Combination Phases of the Improve Study

Lydia Scarfo, Silvia Heltai, Elisa Albi, Eloise Scarano, Luana Schiattone, Lucia Farina, Gianluca Gaidano, Marina Deodato, Andrea Ferrario, Marina Motta, Gianluigi Reda, MD, Rosaria Sancetta, MD, Marta Coscia, MD PhD, Marco Ladetto, MD, Luca Laurenti, MD, Marzia Varettoni, Eleonora Perotta, Antonella Capasso, Pamela Ranghetti, Maria Colia, Paolo Ghia, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–22.
https://doi.org/10.1182/blood-2020-136507
Published: 2020